| Year |
Title |
Altmetric |
| 2022
|
Reply to letter to the editor from Dr. Boers re: Rheumatoid arthritis disease activity and hospitalized infection in a large U.S. registry..
Arthritis Care and Research.
2022
|
|
| 2022
|
Adherence patterns in naïve and prevalent use of infliximab and its biosimilar.
BMC Rheumatology.
6.
2022
|
|
| 2022
|
ISPE-Endorsed Guidance in Using Electronic Health Records for Comparative Effectiveness Research in COVID-19: Opportunities and Trade-Offs.
Clinical Pharmacology and Therapeutics.
112:990-999.
2022
|
|
| 2022
|
Inpatient Diagnosis of Delirium and Encephalopathy: Coding Trends in 2011–2018
2022
|
|
| 2022
|
Patient-Reported Nausea and Fatigue Related to Methotrexate: A Prospective, Self-Controlled Study in the ArthritisPower® Registry.
Rheumatology and Therapy.
9:207-221.
2022
|
|
| 2022
|
Rheumatoid arthritis disease activity and hospitalized infection in a large U.S. registry.
Arthritis Care and Research.
2022
|
|
| 2021
|
The Annual Diagnostic Prevalence of Ankylosing Spondylitis and Axial Spondyloarthritis in the United States Using Medicare and MarketScan Databases.
ACR Open Rheumatology.
3:743-752.
2021
|
|
| 2021
|
Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long-Term Use of Glucocorticoids.
Arthritis Care and Research.
73:1597-1605.
2021
|
|
| 2021
|
Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry
2021
|
|
| 2021
|
Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data from the IBM MarketScan® Administrative Claims Database with Tofacitinib Trial Data.
Inflammatory Bowel Diseases.
27:1394-1408.
2021
|
|
| 2021
|
Meaningful change thresholds for patient-reported outcomes measurement information system (PROMIS) fatigue and pain interference scores in patients with rheumatoid arthritis.
Journal of Rheumatology.
48:1239-1242.
2021
|
|
| 2021
|
Anca-Associated vasculitis management in the united states: Data from the rheumatology informatics system for effectiveness (rise) registry.
Journal of Rheumatology.
48:1060-1064.
2021
|
|
| 2021
|
Evaluation of the Effect of Diabetes on Rheumatoid Arthritis-related Outcomes in an Electronic Health Record-based Rheumatology Registry.
Journal of Rheumatology.
48:992-1001.
2021
|
|
| 2021
|
Benefits of methotrexate use on cardiovascular disease risk among rheumatoid arthritis patients initiating biologic disease-modifying antirheumatic drugs.
Journal of Rheumatology.
48:804-812.
2021
|
|
| 2021
|
Association of anti-tumor necrosis factor therapy with mortality among veterans with inflammatory bowel disease.
JAMA Network Open.
4.
2021
|
|
| 2021
|
Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry.
Arthritis Care and Research.
2021
|
|
| 2020
|
Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study.
ACP journal club.
173:870-878.
2020
|
|
| 2020
|
Use of ICD-10 diagnosis codes to identify seropositive and seronegative rheumatoid arthritis when lab results are not available.
Arthritis Research and Therapy.
22.
2020
|
|
| 2020
|
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Annals of the Rheumatic Diseases.
79:1400-1413.
2020
|
|
| 2020
|
Capture of biologic and biosimilar dispensings in a consortium of U.S.-based claims databases: Utilization of national drug codes and Healthcare Common Procedure Coding System modifiers in medical claims.
Pharmacoepidemiology and Drug Safety.
29:778-785.
2020
|
|
| 2020
|
Duration of Bisphosphonate Drug Holidays and Associated Fracture Risk.
Medical Care.
58:419-426.
2020
|
|
| 2020
|
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.
Drug Safety.
43:379-392.
2020
|
|
| 2020
|
Assessing Rheumatoid Arthritis Disease Activity With Patient-Reported Outcomes Measurement Information System Measures Using Digital Technology.
Arthritis Care and Research.
72:553-560.
2020
|
|
| 2020
|
Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart.
Journal of Bone and Mineral Research.
35:478-487.
2020
|
|
| 2020
|
Do Patients With Moderate or High Disease Activity Escalate Rheumatoid Arthritis Therapy According to Treat-to-Target Principles? Results From the Rheumatology Informatics System for Effectiveness Registry of the American College of Rheumatology.
Arthritis Care and Research.
72:166-175.
2020
|
|
| 2020
|
Factors associated with breast cancer screening behaviors in a sample of Jamaican women in 2013
2020
|
|
| 2020
|
Human papillomavirus vaccination schedule: Adherence among commercially insured adolescents and young adults in the United States, 2011-2017.
American Journal of Public Health.
110:385-390.
2020
|
|
| 2019
|
Screening of Hyperlipidemia Among Patients With Rheumatoid Arthritis in the United States.
Arthritis Care and Research.
71:1593-1599.
2019
|
|
| 2019
|
Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.
Arthritis Care and Research.
71:1249-1254.
2019
|
|
| 2019
|
Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients.
Arthritis Care and Research.
71:1004-1018.
2019
|
|
| 2019
|
Tools and Methods for Real-World Evidence Generation: Pragmatic Trials, Electronic Consent, and Data Linkages.
Rheumatic Disease Clinics of North America.
45:275-289.
2019
|
|
| 2019
|
Improved Quality of Life with Anti-TNF Therapy Compared with Continued Corticosteroid Utilization in Crohn's Disease.
Inflammatory Bowel Diseases.
25:925-936.
2019
|
|
| 2019
|
Perspectives of Rheumatoid Arthritis Patients on Electronic Communication and Patient-Reported Outcome Data Collection: A Qualitative Study.
Arthritis Care and Research.
71:80-87.
2019
|
|
| 2019
|
Which patient reported outcome domains are important to the rheumatologists while assessing patients with rheumatoid arthritis?.
BMC Rheumatology.
3.
2019
|
|
| 2018
|
Socioeconomic Status and Race are both Independently associated with Increased Hospitalization Rate among Crohn's Disease Patients.
Scientific Reports.
8.
2018
|
|
| 2018
|
Use of Medicare Claims Data for the Identification of Myocardial Infarction: The Reasons for Geographic and Racial Differences in Stroke Study.
Medical Care.
56:1051-1059.
2018
|
|
| 2018
|
Is Rheumatoid Arthritis a Cardiovascular Risk-Equivalent to Diabetes Mellitus?.
Arthritis Care and Research.
70:1694-1699.
2018
|
|
| 2018
|
An Observational Study of Cardiovascular Risks Associated with Rheumatoid Arthritis Therapies: A Comparison of Two Analytical Approaches.
The Permanente Journal.
22.
2018
|
|
| 2018
|
Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians.
Drug Safety.
41:545-553.
2018
|
|
| 2018
|
Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept
2018
|
|
| 2018
|
Reply.
Arthritis and Rheumatology.
70:795-796.
2018
|
|
| 2018
|
Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: A population-based study.
Annals of the Rheumatic Diseases.
77:386-392.
2018
|
|
| 2018
|
Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-α-directed therapy for inflammatory bowel disease.
American Journal of Gastroenterology.
113:405-417.
2018
|
|
| 2018
|
Comparative Effectiveness of Vedolizumab vs. Infliximab Induction Therapy in Ulcerative Colitis: Experience of a Real-World Cohort at a Tertiary Inflammatory Bowel Disease Center..
Gastroenterology Research.
11:41-45.
2018
|
|
| 2017
|
Accuracy of Medicare Claim-based Algorithm to Detect Breast, Prostate, or Lung Cancer Bone Metastases..
Medical Care.
55:e144-e149.
2017
|
|
| 2017
|
Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty.
Arthritis Care and Research.
69:1845-1854.
2017
|
|
| 2017
|
Is gout a risk equivalent to diabetes for stroke and myocardial infarction? A retrospective claims database study.
Arthritis Research and Therapy.
19.
2017
|
|
| 2017
|
Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis.
Arthritis Care and Research.
69:1526-1534.
2017
|
|
| 2017
|
Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States.
Arthritis and Rheumatology.
69:1733-1740.
2017
|
|
| 2017
|
Availability of healthcare resources and epithelial ovarian cancer stage of diagnosis and mortality among Blacks and Whites.
Journal of Ovarian Research.
10.
2017
|
|
| 2017
|
Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases.
Journal of Rheumatology.
44:1083-1087.
2017
|
|
| 2017
|
The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights.
Pharmacoepidemiology and Drug Safety.
26:310-319.
2017
|
|
| 2017
|
Herpes Zoster and the Risk of Stroke in Patients With Autoimmune Diseases.
Arthritis and Rheumatology.
69:439-446.
2017
|
|
| 2017
|
Accuracy of Medicare Claim-based Algorithm to Detect Breast, Prostate, or Lung Cancer Bone Metastases.
Medical Care.
55:e144-e149.
2017
|
|
| 2016
|
Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
Arthritis and Rheumatology.
68:2612-2617.
2016
|
|
| 2016
|
Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study.
Arthritis and Rheumatology.
68:2403-2411.
2016
|
|
| 2016
|
Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.
Annals of the Rheumatic Diseases.
75:1813-1818.
2016
|
|
| 2016
|
Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
Annals of the Rheumatic Diseases.
75:1843-1847.
2016
|
|
| 2016
|
Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination.
Arthritis and Rheumatology.
68:2328-2337.
2016
|
|
| 2016
|
LDL cholesterol response and statin adherence among high-risk patients initiating treatment.
American Journal of Managed Care.
22.
2016
|
|
| 2016
|
Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer.
JAMA Dermatology.
152:164-172.
2016
|
|
| 2016
|
Comparative Risk of Hospitalized Infection Associated with Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Arthritis and Rheumatology.
68:56-66.
2016
|
|
| 2016
|
LDL cholesterol response and statin adherence among high-risk patients initiating treatment.
American Journal of Managed Care.
22:e106-e115.
2016
|
|
| 2016
|
Risk of Cardiovascular Outcomes among Psoriasis Patients Treated with Biologics and Other Systemic Agents.
2016
|
|
| 2015
|
The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population.
British Journal of Clinical Pharmacology.
80:1447-1457.
2015
|
|
| 2015
|
Reply.
Arthritis Care and Research.
67:1041-1042.
2015
|
|
| 2015
|
Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
Annals of the Rheumatic Diseases.
74:1065-1071.
2015
|
|
| 2015
|
Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
Arthritis and Rheumatology.
67:1456-1464.
2015
|
|
| 2015
|
Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
Arthritis Care and Research.
67:624-632.
2015
|
|
| 2015
|
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.
Arthritis Care and Research.
67:731-736.
2015
|
|
| 2015
|
Statin use following hospitalization among Medicare beneficiaries with a secondary discharge diagnosis of acute myocardial infarction.
Journal of the American Heart Association.
4.
2015
|
|
| 2015
|
Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.
Journal of managed care & specialty pharmacy.
21:318-328.
2015
|
|
| 2015
|
Fractures and mortality in relation to different osteoporosis treatments.
Clinical and Experimental Rheumatology.
33:302-309.
2015
|
|
| 2015
|
Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease.
Journal of the American College of Cardiology.
65:270-277.
2015
|
|
| 2014
|
Linkage of a de-identified united states rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research.
Arthritis Care and Research.
66:1790-1798.
2014
|
|
| 2014
|
Use of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United States.
Arthritis Care and Research.
66:1604-1611.
2014
|
|
| 2014
|
Ability of low antihypertensive medication adherence to predict statin discontinuation and low statin adherence in patients initiating treatment after a coronary event.
American Journal of Cardiology.
114:826-831.
2014
|
|
| 2014
|
Estimating effectiveness and cost of biologics for rheumatoid arthritis: Application of a validated algorithm to commercial insurance claims
2014
|
|
| 2014
|
Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries.
BMC Musculoskeletal Disorders.
15.
2014
|
|
| 2014
|
Death, debility, and destitution following hip fracture
2014
|
|
| 2014
|
Ability of low antihypertensive medication adherence to predict statin discontinuation and low statin adherence in patients initiating treatment after a coronary event..
American Journal of Cardiology.
114:826-831.
2014
|
|
| 2014
|
Declines in coronary heart disease incidence and mortality among middle-aged adults with and without diabetes.
Annals of Epidemiology.
24:581-587.
2014
|
|
| 2014
|
Statin underuse and low prevalence of LDL-C control among U.S. Adults at high risk of coronary heart disease.
American Journal of the Medical Sciences.
348:108-114.
2014
|
|
| 2014
|
Trends in the utilization and outcomes of medicare patients hospitalized for hip fracture, 2000-2008.
Journal of Aging and Health.
26:360-379.
2014
|
|
| 2014
|
Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis
2014
|
|
| 2013
|
Identifying newly approved medications in Medicare claims data: A case study using tocilizumab.
Pharmacoepidemiology and Drug Safety.
22:1214-1221.
2013
|
|
| 2013
|
Awareness, treatment, and control of LDL cholesterol are lower among U.S. adults with undiagnosed diabetes versus diagnosed diabetes.
Diabetes reviews (Alexandria, Va.).
36:2734-2740.
2013
|
|
| 2013
|
Trends in the prevalence, awareness, treatment and control of high low density lipoprotein-cholesterol among United States adults from 1999-2000 Through 2009-2010.
American Journal of Cardiology.
112:664-670.
2013
|
|
| 2013
|
New methods for determining comparative effectiveness in rheumatoid arthritis.
Current Opinion in Rheumatology.
25:325-333.
2013
|
|
| 2013
|
Further evaluation of a claims-based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data.
Arthritis Research and Therapy.
15.
2013
|
|
| 2013
|
Physicians' explanations for apparent gaps in the quality of rheumatology care: Results from the US Medicare Physician Quality Reporting System.
Arthritis Care and Research.
65:235-243.
2013
|
|
| 2013
|
Generic alendronate use among medicare beneficiaries: Are part d data complete?.
Pharmacoepidemiology and Drug Safety.
22:55-63.
2013
|
|
| 2013
|
Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program.
Arthritis Care and Research.
65:1743-1751.
2013
|
|
| 2012
|
Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data.
Arthritis Care and Research.
64:1855-1863.
2012
|
|
| 2012
|
Recent trends in hip fracture rates by race/ethnicity among older US adults.
Journal of Bone and Mineral Research.
27:2325-2332.
2012
|
|
| 2012
|
Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare population.
Arthritis Care and Research.
64:1054-1060.
2012
|
|
| 2012
|
Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changes.
Journal of Bone and Mineral Research.
27:858-864.
2012
|
|
| 2011
|
Minor, Major, Low-Trauma, and high-trauma fractures: What are the subsequent fracture risks and how do they vary?.
Current Osteoporosis Reports.
9:122-128.
2011
|
|
| 2011
|
Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies.
Current Rheumatology Reports.
13:273-282.
2011
|
|
| 2011
|
Erratum: Clinical and demographic factors associated with fractures among older Americans (Osteoporosis International DOI: 10.1007/s00198-010-1300-8).
Osteoporosis International.
22:1275-1276.
2011
|
|
| 2011
|
Clinical and demographic factors associated with fractures among older Americans.
Osteoporosis International.
22:1263-1274.
2011
|
|
| 2010
|
Predicting hip and major osteoporotic fractures using administrative data.
JAMA Internal Medicine.
170:1940-1942.
2010
|
|
| 2010
|
Health services utilization after fractures: Evidence from Medicare
2010
|
|
| 2010
|
Identifying types of nursing facility stays using medicare claims data: An algorithm and validation
2010
|
|
| 2009
|
Health care expenditures associated with skeletal fractures among medicare beneficiaries, 1999-2005.
Journal of Bone and Mineral Research.
24:2050-2055.
2009
|
|
| 2009
|
Estimated prevalence and patterns of presumed osteoporosis among older Americans based on Medicare data.
Osteoporosis International.
20:1507-1515.
2009
|
|
| 2009
|
The effects of the Balanced Budget Act of 1997 on home health and hospice in older adult cancer patients.
Medical Care.
47:279-285.
2009
|
|
| 2008
|
Adaptation of bayesian data mining algorithms to longitudinal claims data: Coxib safety as an example.
Medical Care.
46:969-975.
2008
|
|
| 2008
|
Does cholecystectomy prior to the diagnosis of pancreatic cancer affect outcome?
2008
|
|
| 2008
|
Secondary Analysis of Merged American Hospital Association Data and U.S. Census Data: Beginning to Understand the Supply-Demand Chain in Pediatric Inpatient Care.
Journal of Pediatric Nursing.
23:161-168.
2008
|
|
| 2006
|
Trends in hospital and surgeon volume and operative mortality for cancer surgery.
Annals of Surgical Oncology.
13:851-858.
2006
|
|
| 2005
|
Physician supply, treatment, and amputation rates for peripheral arterial disease.
Journal of Vascular Surgery.
42:81-87.
2005
|
|
